CRISIL reaffirms 'A1+' rating on the bank facilities and debt programme of Ranbaxy Laboratories.

The rating continues to reflect Ranbaxy's established position in the international generics market and in the Indian formulations market. The rating also factors in the business synergies with its parent, Daiichi Sankyo Company (Daiichi), one of the leading innovator pharmaceutical companies in Japan.

These rating strengths are partially offset by Ranbaxy's exposure to growing competition and regulatory risks in the regulated generics markets of USA and Europe, and susceptibility to fluctuations in foreign currency exchange rates on option contracts.

Shares of the company gained Rs 2.45, or 0.7%, to trade at Rs 351. The total volume of shares traded was 95,567 at the BSE (11.37 a.m., Tuesday).